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A
ctive speciﬁc immunotherapies (vac-
cines)takeadvantageoftheabilityof
theimmunesystemtorecognizeand
react with foreign antigens. In the case of
cancer vaccines, the antigens typically are
not foreign, but overexpressed self-antigens
on thesurface or inside thetumor cell, some
of which are then presented on the cell
surface in the context of HLA molecules for
recognitionbyT-cells.
1,2Thegenerationofan
immuneresponsegenerallyrequirespeptide
presentation by dendritic cells (DCs), which
are the most eﬀective antigen presenting
cells (APCs).
3,4 Tumor self-antigens are gen-
erally poorly immunogenic and the host
bearing the tumor either does not recognize
the antigen or is tolerant to it.
5,6 While a
number of strategies have been used to en-
hance the immunogenicity of tumor pep-
tide antigens and break the self-tolerance,
soluble peptides are poor immunogens, and
eﬀectiveimmunizationstrategiesrequirede-
livery formulations that include carrier mol-
ecules or adjuvants. Great advances have
been made within the past decade in the
discovery of new adjuvants suitable for clin-
icaluse,includingcytokines,
7saponins,CpG
motifs,
8 and heat shock proteins
9 that can
stimulate the innate immune system and
induce strong adaptive immune responses.
However, their biological activities are nor-
mally short-lived, requiring several doses to
be administered. Materials made from syn-
theticandnaturalsourcessuchasdendrimers
or keyhole limpet hemocyanin (KLH), have
been proposed as potential carrier mole-
cules.
10,11 The potent immunogenicity and
lack of ﬂexibility of these carrier molecules
can lead to the problem of carrier-induced
suppression. The host immune system be-
comes overwhelmed with the maintenance
of a polyclonal response to the carrier mo-
lecule, thereby limiting the ability to gener-
ate a focused response to the antigen of
choice, which is detrimental to the eﬃcacy
of the vaccine.
12 Thus, there is a need for
newcarriers,especiallythosethateﬃciently
deliver the antigens into professional APCs,
such as DCs.
A promising approach to improve the
immunogenicity of proteins and peptides
for cancer vaccines is the use of particulate
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ABSTRACT Westudiedthefeasibilityofusingsingle-wallcarbonnanotubes(SWNTs)asantigen
carriers to improve immune responses to peptides that are weak immunogens, a characteristic
typical of human tumor antigens. Binding and presentation of peptide antigens by the MHC
moleculesofantigenpresentingcells(APCs)isessentialtomounting aneﬀectiveimmuneresponse.
The Wilm's tumor protein (WT1) is upregulated in many human leukemias and cancers and several
vaccines directed at this protein are in human clinical trials. WT1 peptide 427 induces human CD4 T
cell responses in the context of multiple human HLA-DR.B1 molecules, but the peptide has a poor
binding aﬃnity to BALB/c mouse MHC class II molecules. We used novel, spectrally quantiﬁable
chemical approaches to covalently append large numbers of peptide ligands (0.4 mmol/g) onto
solubilizedSWNTscaﬀolds.Peptide-SWNTconstructswererapidlyinternalizedintoprofessionalAPCs
(dendritic cells and macrophages) within minutes in vitro, in a dose dependent manner.
Immunization of BALB/c mice with the SWNT peptide constructs mixed with immunological
adjuvant induced speciﬁc IgG responses against the peptide, while the peptide alone or peptide
mixedwiththeadjuvantdidnotinducesucharesponse.TheconjugationofthepeptidetoSWNTdid
not enhance the peptide-speciﬁc CD4 T cell response in human and mouse cells, in vitro. The
solubilized SWNTs alone were nontoxic in vitro, and we did not detect antibody responses to SWNT
invivo.TheseresultsdemonstratedthatSWNTsareabletoserveasantigencarriersfordeliveryinto
APCs to induce humoral immune responses against weak tumor antigens.
KEYWORDS: carbon nanotubes . nanomedicine . Wilms' tumor antigen . peptide
vaccines . dendritic cells
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vaccines.
13 Conjugation of antigenic epitopes to parti-
culate scaﬀolds has shown that the particles improve
immune responses and that the response is most
improved when the particles are on the nanoscale.
14
This discovery has introduced the concept of nanovac-
cines, where changes in the nanoscale architecture of
particulate vaccine materials can direct the character-
istics of the immune response.
15 An important charac-
teristicofnanovaccinesistheirenhancementofdelivery
to APCs. Antigen delivery through nanoparticles also
alters cellular traﬃcking and can serve as an intracellu-
lardepotofantigen,bothofwhichimprovetheimmune
response to the delivered antigen. However, most stud-
ies of nanoparticulate vaccines have used the strongly
immunogenic,eggprotein,OVAasthemodelantigenin
initial investigations; peptides derived from this foreign
protein are already known to be highly immunogenic.
As a nanomaterial of unique physical and chemical
properties, carbon nanotubes have attracted consider-
able interest in biomedical applications,
16 including
their use as nanovaccine scaﬀolds. Because of their
propensitytointernalizeintoawidevarietyofcelltypes
and through several mechanisms,
17 19 they appear to
be particularly suited to deliver antigenic epitopes to
APCs. In addition, carbon nanotubes have a unique
geometry (very high aspect ratio) that may inherently
alter the immunogenicity of appended antigens. Sin-
gle-walledcarbonnanotubes(SWNTs)alsohavealarge
available surface area for chemical modiﬁcation, with
every atom inherentlyatthe nanotube surface. Further-
more, well-functionalized, dispersed carbon nanotubes
donot appearto have inherenttoxicity
20(incontrast to
unmodiﬁed carbon nanotubes
21), and can bear large
numbersofpeptideligands.Thereisalsoevidencethat
carbon nanotubes can produce immune responses
when covalently linked to highly immunogenic pep-
tidesequences.
22However,therearenoreportsonthe
use of carbon nanotubes (CNTs) to deliver antigen to
primaryhumanDCs,northedemonstrationofimprove-
ment of immunogenicity of therapeutically relevant
antigensadministeredwithcommonadjuvants.Further-
more, there is continuing debate about the inherent
immunogenicityofSWNTsandtheirabilitytoaugment
immune responses.
23
In the current study, we aimed to demonstrate that
carbon nanotube peptide constructs could improve
the immunogenicity of a weakly immunogenic, clini-
cally relevant cancer-associated peptide. Wilm's tumor
antigen(WT1)iswidelyusedinhumantrialsasacancer
vaccine.
24 26 A 19 amino acid peptide named WT1-
Pep427 derived from WT1 protein was chosen for
study because the peptide has high binding aﬃnity
across multiple human HLA-DR haplotypes and in-
duces strong CD4 T cell responses in humans, but is a
poor binder to both I-Ed and I-Ad class II molecules of
BALB/c mice. We used spectrally quantiﬁable chemical
approaches to covalently append large numbers of
peptide ligands onto solubilized SWNT scaﬀolds. The
SWNTs were covalently modiﬁed on their sidewalls
with hydrophilic ethylene glycol using 1,3-dipolar
cycloaddition of azomethine ylides. We then investi-
gated the kinetics and cellular pharmacology of the
nanotube interaction with APCs in vitro; ﬁnally we
asked whether these nanotube peptide conjugates
could improve immune responses in vivo in mice. We
also demonstrated that the nanotube scaﬀold itself
is noncytotoxic to human dendritic cells and is
nonimmunogenic.
RESULTS
Synthesis and Characterization of SWNT 4FB. The syn-
thetic scheme for the nanotube peptide conjugates
used in this study is shown (Figure 1). SWNTs covalent-
ly functionalized with primary amines (SWNT NH2)
were produced as described previously.
27 In previous
studies
28 we characterized the physical properties of
identically prepared SWNT NH2 material and the chro-
matographic methods used to prepare it. Thissynthetic
scheme reproducibly produces functionalized SWNTs
in the size range of 50 400 nm. The SWNT NH2
material was a dark brown solid whose amine content
was 0.4 0.6 mmol/g, as quantified through the Kaiser
ninhydrinassayandinagreementwithprevioussynth-
eses.Thepuritywas>90%,asverifiedbyreversephase
HPLC (Figure 1b). The solid SWNT NH2 was analyzed
using Raman spectroscopy which demonstrated that
the nanotubes were highly functionalized, evidenced
byariseinthedisorderbandat∼1360cm
 1,aswellas
the major tangential mode peak at ∼1580 cm
 1, char-
acteristicofCNTs.Thebroadeningofthesepeaksalong
with a broad increase in background signal also con-
firmed that the SWNTs were highly dispersed. The
SWNT NH2 was then reacted with succinimidyl-4-for-
myl-benzoate, and the resulting aldehyde functiona-
lized nanotubes (SWNT 4FB) were analyzed by reverse
phase HPLC (Figure 2b) that demonstrated the high
purity (>90%) of the material as well as similar reten-
tiontimetothestartingSWNT NH2.Theconversionto
aldehyde groups was also evident in the reduction of
availableaminestolessthan0.05mmol/gasmeasured
by the Kaiser ninhydrin assay. The SWNT 4FB solid
wasalsoanalyzedbytransmissionelectronmicroscopy
(TEM) (Figure 2c) to roughly determine nanotube
lengths and found aggregates of nanotubes in the
rangeon50 400nm,withhighvariabilityinnanotube
length. This finding was in good correlation with sizes
calculated from dynamic light scattering measure-
ments on similarly functionalized SWNTs.
28 We also
observed that individualized side-wall functionalized
SWNTs had poor contrast on TEMs, likely due to
reduced electron density upon covalent modification,
making it difficult to observe individual tubes.
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Modification of WT1Pep427. A WT1 epitope bearing
peptide (WT1Pep427, sequence: NH2-RSDELVRHHN-
MHQRNMTKL-COOH) was chosen based on previous
studies that demonstrated that the peptide contains
sequences capable of binding to MHC class II proteins
(seeabove).Thepeptidewasreactedwithsuccinimidyl
hydrazino nicotinamideat mildly basic pH(Figure 1) to
introduce aromatic hydrazines at the amino terminus
of the peptide, while avoiding modification of the
lysine side chains (pKa >10). The purity of the modified
hydrazine modified peptide was >95% as determined
by C18 reverse phase HPLC. The presence of hydrazine
in the peptide was quantified through reaction with
2-sulfobenzaldehyde to form a quantifiable chromo-
phore of λmax = 350 nm. The remaining primary amine
onthelysinesidechainwasquantifiedthroughaKaiser
ninhydrin assay. These analyses found a 1:1 ratio of
hydrazine to amine, suggesting monomolecular mod-
ification at the amine terminus, with preservation of
amines on lysine side chains.
Conjugation of SWNT 4FB with WT1Pep427-HyNic. The
SWNT 4FB and WT1Pep427-HyNic were conjugated
by reaction at mildly acidic pH. The addition of 20%
acetonitrile to the reaction mixture helped to reduce
aggregation of the nanotubes that had been observed
insimilarconcentratedaqueousreactions.TheSWNT 
WT1Pep427 conjugate was purified from free
WT1Pep427 HyNic by use of a C18 reverse-phase
c a r t r i d g ea n da n a l y z e db yU V  vis spectroscopy.
The absorbance spectrum demonstrated features of
theexpectedSWNTspectrum,aswellasariseinabsor-
bance at 354 nm attributable to the formation of the
bis-aryl hydrazone linkage between the peptide and
nanotube (Figure 2a). This difference in absorbance
was quantifiable by subtraction of the spectrum of
SWNT NH2. This calculation resulted in a peptide
loadingof0.4 0.5mmolofpeptidepergramofSWNT,
inlinewiththeinitial loadingofprimaryaminegroups.
This loading represents roughly 50 75 peptides per
100nmofnanotubelengthbasedontypicalmolecular
weights of SWNTs. The purity of the material was con-
firmed by HPLC (Figure 2b), which also demonstrated
thatthebis-arylhydrazonebondswereassociatedwith
the SWNTs based on the spectrum of the major peak
and retention time similar to SWNTs starting material.
HPLC also confirmed that the SWNT WT1Pep427
conjugates did not contain free peptide, which would
have eluted in the first 10 min of the solvent gradient.
Uptake of SWNT into Human Dendritic Cells. Peripheral
blood mononuclear cells were isolated from normal
humandonorsandculturedinthepresenceofGM-CSF
and IL-4 to induce differentiation into immature den-
dritic cells. SWNT 4FB solid was dissolved in DMSO
and then diluted into PBS. The SWNT 4FB solution in
PBSwasthenaddedtoimmatureDCs(day5)atarange
of concentrations from 0 to 100 μg/mL. The amount of
DMSO in the final incubation conditions was always
<0.15%. Control DCs were treated with identical vo-
lumes and concentrations of DMSO/PBS. Because the
functionalized SWNTs possess inherent fluorescence
across a range of excitation/emission wavelengths,
29
uptake could be monitored using flow cytometry, and
signal from the SWNTs can be seen as an increase in
fluorescenceinanyofthetypicalchannels(FL2andFL3
Figure1. SyntheticschemefortheproductionofSWNT peptideconjugatesandmodiﬁcationofWT1Pep-427witharomatic
hydrazine groups.
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are shown), or an increase in side-scattering intensity
(duetolightscatteredbytheinternalizedSWNTs).There
was a dose-dependent increase in both cell-associated
side-scatter and fluorescence in all channels (Figure
3a c).Furthermore,uptakeasmeasuredbytheshiftin
median fluorescence continued to increase at the
highest dose (Figure 3d). There was no change in the
forward-scattering intensity, suggesting no significant
change in the cellular size.
To further deﬁne the uptake kinetics, mechanism,
and cellular traﬃcking pattern of nanotube constructs,
immature dendritic cells (day 5) were incubated with
ﬂuorescentlylabeledSWNTsat1 10μg/mL.Cellswere
then observed live, in real-time, using a temperature
controlled confocal microscope imaging system. The
characteristic morphology of the dendritic cells was
evident. (Figure 4a.) We observed that uptake into the
dendriticcellswasimmediate(within5min),andhada
punctate pattern. Initial uptake on the periphery ofthe
DCs appeared vesicular (Figure 4a c, white arrows),
and occurred within the ﬁrst 15 min of addition of the
SWNT constructs. After 15 min, the ﬂuorescently la-
beled nanotubes accumulated in a diﬀuse perinuclear
compartment (Figure 4a c, arrowheads). This pattern
of uptake was the same for either amine (SWNT 
NH2 AF555, Figure 4a) or aldehyde (SWNT 4FB 
AF568, Figure 4b)-functionalized SWNTs. The kinetics
and pattern of cellular traﬃcking was veriﬁed by using
two diﬀerently labeled SWNTs. Cells were ﬁrst treated
with a red-labeled SWNT (SWNT 4FB AF568) con-
struct for 30 min, washed, then treated with a green-
labeled SWNT contruct (SWNT NH2 AF488) and im-
mediately imaged. The resulting image of this trea-
ment (Figure 4c) shows the early peripheral uptake in
the green vesicles (Figure 4c-arrow) as well as the late
accumulation of SWNTs in the red-stained perinucelar
compartment (Figure 4c-arrowhead). This pattern of
traﬃcking was also seen in similarly treated macro-
phages (Figure 4d).
The perinuclear compartment in the immature DCs
was also relatively acidic, as it stained diﬀusely with a
green lysosomal marker (Lysotracker green), and colo-
calized with the perinuclear uptake of red-labeled
SWNT 4FB AF568 constructs (Figure 4e). Lysosomes
inimmaturedendriticcellsareknowntobesitesrichin
intracellular MHC classIImolecules.
33 Interestingly, the
cellular fate of internalized SWNTs was diﬀerent in a
Rastransformedﬁbroblastcellline(NIH-3T3,Figure4f),
where internalized SWNTs did not colocalize with
lysosomal compartments or accumulate in a perinuc-
lear compartment.
Therapid,robust,andvesicularuptakeisconsistent
with macropinocytosis, known to be an important
mechanism of macromolecular antigen uptake in im-
mature dendritic cells.
30,31 Macropinocytosis in DCs is
also known to concentrate macromolecules in intra-
cellular vesicles and to traﬃc antigens to MHC class II
rich compartments, desirable for antigen delivery. Pha-
gocytosis, such as through mannose receptors, contri-
butes additional capacity for antigen capture in DCs
and may also contribute to SWNT uptake. Macropino-
cytosis ingrowth factor stimulated epithelialcells does
not necessarily result in delivery to late endosomes or
lysosomes,
32 likely explaining why the SWNTs did not
colocalize with lysosomal markers in the Ras trans-
formed ﬁbroblasts.
To diﬀerentiate between receptor-independent
andreceptor-dependent (clathrinmediated)pinocyto-
tic uptake mechanisms, DCs were treated with
Figure 2. Characterizationof functionalized SWNTs. (a) UV 
visspectrumofSWNT WT1Pep427(solidline)demonstrates
a rise in absorbance at ∼354 nm over the SWNT 4FB spec-
trum (dashed line). This peak is characteristic of the bis-aryl
hydrazone bond formed between the modiﬁed peptide and
theSWNT 4FB.(b)ReversephaseHPLCofthestartingmate-
rialSWNT NH2 (black),the SWNT 4FBintermediate(red),
andtheSWNT WT1Pep427conjugate (blue)demonstrate
thepurityofthethreeconstructs.Allpeaksoverlaid,andthe
spectrumofthemajorpeakofSWNT WT1Pep427wascon-
sistent with the spectrum of the SWNT WT1Pep427 shown
above in panel a. (c) TEM of the SWNT 4FB used in these
studies shows a polydisperse mixture with features char-
acteristic of nanotubes.
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ﬂuorescently labeled transferrin, a marker for clathrin-
mediated endocytosis, along with labeled SWNT con-
structs.TherewasminimalcolocalizationwithTfaround
theperipheryofthedendriticcells(Figure4g),butsome
colocalization was seen in late accumulation in a peri-
nuclearcompartment(Figure4h).Thisﬁndingsuggests
that receptor-mediated (clathrin dependent) endocyto-
sis is a relatively minor contributor to the uptake of
SWNTsbyantigenpresentingcells.Receptor-mediated
endocytosis inDCs can share the same ultimate fate as
receptor-independent processes, which explains the
late intracellular colocalization of SWNTs with Tf. While
othermechanismsofuptake,suchasdirectmembrane
permeation, for SWNTs have been described,
17 it ap-
pears that in antigen presenting DCs, these pathways
are minor contributors incomparison to the rapidity of
macropinocytotic accumulation.
These ﬁndings suggest that in antigen presenting
cells, SWNT constructs are traﬃcked to a degradative
perinuclear region, likely through macropinocytosis, re-
sulting in accumulation in a lysosomal perinuclear com-
partment. Phagocytosis may also contribute to inter-
nalization into DCs. These MHC class II-rich compart-
ments are known sites of peptide processing, such as
cleavage by cathepsins, for subsequent loading into
MHC II proteins for presentation on the cell surface
uponmaturationoftheDCs.
33,34Toconﬁrmthatpeptide
can be delivered to this compartment when covalently
attached to SWNTs, dendritic cells were similarly trea-
tedwithSWNT WT1Pep427(FITC)conjugatesinwhich
the peptide was labeled with a ﬂuorescein moiety on
its lysine side chain. The nanotube was directly labeled
with a near-infrared ﬂuorophore (HiLyte Fluor 647).
After treatment with the conjugate for 2.5 h, the cells
were washed, ﬁxed with neutral buﬀered formalin, stained
with DAPI, and observed under a confocal microscope. A
maximum intensity projection of a 10 μm thick section
through a representative DC (Figure 4i) demonstrates
that the peptide (green) and SWNT (red) colocalize to
produce yellow staining in peripheral vesicles and a
perinuclear compartment in similar fashion to that
previouslyobservedwithlivecells.Thestainingclosest
to the nucleus (Figure 4i, arrowhead) was stronger in
the red channel (the SWNT) than the green (the
peptide), suggesting cleavage of the peptide from
the SWNT in the late vesicles. These microscopy ana-
lyses suggest that SWNT peptide constructs are con-
centrated in intracellular vesicles in DCs, potentially
enhancing peptide delivery into APCs.
Figure 3. Internalization could be observedthrough (a) an increasein side-scatter intensity with increasing doses (0, red; 10,
orange; 50, green; and 100 μg/mL, blue) and an increase in ﬂuorescence intensity due to the broad intrinsic ﬂuorescence of
theSWNT 4FB.Fluorescenceinchannel(b)FL2and(c)FL3areshown.(d)Theincreaseinﬂuorescencecouldbequantiﬁedas
the shift in median ﬂuorescence.
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Cytotoxicity of SWNT Constructs. Although robust up-
take of SWNTs into DCs is favorable for the delivery of
antigen into the cells, it was also important to demon-
strate that the SWNTs themselves did not affect im-
mature DC viability so that their antigen processing
and presenting function is preserved. To measure any
potential cytotoxic effect of SWNTs, immature (day 5)
DCs were treated with varying concentrations of the
SWNT 4FB scaffold up to 100 μg/mL. Cellular viability
was assessed through an alamar blue assay for cellular
metabolic activity, an ATP lite assay for cellular ATP
production, anda bisbenzimide stainfor cellular apop-
tosis (Figure 5). Treatment with SWNT 4FB up to 100
μg/mL did not demonstrate any dose-dependent cy-
totoxicity in any of the three assays. Cells were treated
for up to 48 h without cytotoxic effects, a time scale
long enough for internalization, processing, and pre-
sentation of antigen to immune effectors. At 48 h, the
Figure4. TrackingtheinternalizationofSWNTconstructsintoDCsbyconfocalmicroscopy.Internalizationfollowedapattern
of early peripheral vesicular uptake (white arrows), with transport to a perinuclear region (white arrowheads). Nuclei were
counterstained with Hoechst (a h) or DAPI (i). Cells were imaged live after 30 min incubation unless otherwise noted. Live
DCs were treated with either (a) SWNT NH2 AF555 (red), or (b) SWNT 4FB AF568 (red). No diﬀerence in uptake pattern
was seen between the aldehyde and amine functionalized SWNTs. To track early and late uptake, DCs were treated with (c)
SWNT 4FB AF568 (red) for 30 min, washed, treated with SWNT NH2 AF488 (green), and immediately imaged. Similarly,
macrophages were treated with (d) SWNT 4FB AF568 (red) for 30 min, washed, treated with SWNT NH2 AF488 (green),
and immediately imaged. For counterstaining studies, DCs were treated with (e) SWNT 4FB AF568, washed after 30 min,
and stained with Lysotracker (green), or NIH-3T3 ﬁbroblast cells were treated with (f) SWNT AF488 NH2 (green) and
Lysotracker (red). To track clathrin-mediated endocytosis, DCs were treated with both (g) SWNT AF488 NH2 (green) and
Texas red labeled Transferrin (red) and immediately imaged, or DCs were treated with both (h) SWNT AF488 NH2 (green)
andTexasredlabeledTransferrinfor30min,washed,andimagedthereafter.TotracktheuptakeofSWNT peptideintoDCs,
the SWNT was labeled with hiLyte Fluor 647 (red) and the attached peptide was labeled with ﬂuorescein (green). DCs were
then treated with SWNT WT1Pep427(FITC) conjugate for 2.5 h, washed, ﬁxed, stained with DAPI, and observed under a
confocal microscope. A maximum intensity projection of a 10 μm thick section through a representative DC can be seen in
paneli. Costaining inendocytic vesiclescan be seen as thepunctateyellowstructures (arrow),while later perinuclear uptake
appears stronger in the red channel (arrowhead).
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darkcoloroftheSWNTconstructswasvisibleinsidethe
immatureDCwhendirectlyobservedunderlightmicro-
scopy. The prolonged retention of SWNTs in viable DCs
also suggests that the internalized SWNT WT1Pep427
particles could serve as an intracellular reservoir of
antigenic peptides. Overall, the results suggested that
dendritic cells could internalize a large amount of
SWNTs without compromising cellular integrity.
SWNT peptide Generation of Human CD4 T Cell Response in
Vitro. Having shown that SWNTs could be internalized
by immature DCs without affecting cellular viability, it
wasimportanttodemonstratethatinternalizedSWNT 
peptide conjugates could induce peptide-specific im-
mune responses. WT1-derived peptide WT1Pep427
(WT1Pep427) was identified in human studies as a
valid CD4 T cell epitope with strong binding affinities
to multiple HLA-DR.B1 molecules.
24 The peptide was
showntoinducestrongCD4Tcellresponsesinhumans
across a broad range of HLA-DR.B1 haplotypes. To test
the impact of the SWNT conjugation on CD4 T cell
response in vitro, we compared WT1Pep427 peptide
alone with the peptide/SWNT conjugates in CD4 T cell
stimulation and IFN-γ secretion. The WT1Pep427 pep-
tide alone induced a strong CD4 T cell response, as
shown previously.
24 26 Conjugating a peptide to a
SWNT maintained, but did not enhance, the CD4 T cell
response in vitro (Figure 6A). This suggests that once
the T cell receptor (TCR) signaling reached a sustained
level for its activation, increasing the density of the
peptide/MHC complex (pMHC), mediated by SWNT
delivery, was no longer required. This is an intrinsic
property of T cell activation, as T cells need to recognize
and respond to cognate pMHC ligands only at low
densityontheAPCsurface.Ontheotherhand,although
we expect the peptide to be cleaved from SWNTs in
APCs, this process may have not been complete and
thus may have affected the MHC binding and the
presentationbyAPCstoTcells,resultinginareduction
of the CD4 T cell response. Importantly, stimulating
CD4 T cells with SWNTs alone did not generate any
responses against either the SWNTs or the peptide,
indicating that the SWNTs are not immunogenic.
One possible explanation for the above experi-
ments was that the stimulus was presented through-
out the duration of culture and therefore, CD4 T cells
may have been constantly exposed to a large amount
of peptide stimulation. Therefore, we next tested if
SWNTcouldenhancetheCD4Tcellresponseinasetting
of a shorter stimulation through kinetic enhancement
of peptide delivery. For this purpose, autologous APCs
were pulsed with the peptide, SWNT, or the peptide/
SWNT construct for 6 h, 1 h, or 15 min, and the cells
were washed extensively before coculturing with CD4
Tcells.Inallthetimepoints,peptidespeciﬁcresponses
could be produced. However, conjugation of peptide
to SWNT again did not produce further enhancement
oftheCD4TcellIFN-γsecretion.Figures6Band6Cshow
representative data from 1 h and 15 min stimulations,
respectively. These results suggested that the TCR sti-
mulation of the WT1Pep427 peptide quickly reached
saturation in the given durations and stimulation do-
sages, and conjugation to SWNT therefore maintained
butdidnotfurtherenhancetheantigenicstimulation in
vitro in human cells. Because SWNT peptide conju-
gates were able to induce CD4 responses to known
immunogenicantigensinhumancellsinvitrowethere-
fore wanted to address the question of the SWNT 
peptide conjugates' ablility to enhance the immune
response in mice, both in vitro and in vivo, where
WT1Pep427 in known to be a weakly immunogenic
antigen.
Peptide/SWNT Construct Induces a Peptide-Specific IgG Re-
sponse in Vivo. We next tested the hypothesis that the
SWNT conjugation would enhance the delivery of a
weakantigenicpeptideandhelpelicitpeptide-specific
Figure 5. Cytotoxicity assay of SWNT 4FB in immature den-
dritic cells. No dose dependent cytotoxicity was observed up
to100μg/mL(at 24,48,and72hof treatmentwithSWNTs)
whenassayedby(a)alamarblueassay,(b)ATPlyteassay,or
(c) bisbenzimide apoptosis assay.
A
R
T
I
C
L
EVILLA ET AL. VOL. 5 ’ NO. 7 ’ 5300–5311 ’ 2011
www.acsnano.org
5307
immuneresponses in vivo. Although WT1Pep427 hasa
strong affinity for human HLA-DR.B1 molecules, the
peptide has a poor binding affinity to both I-Ed and
I-Ad MHC class II molecules of BALB/c mice, and thus
would be an ideal model peptide to address the ques-
tion in these mice. The binding scores of the peptide
to I-Ed and for I-Ad molecules are as low as 17.8
and  0.65, respectively, by RANKPEP prediction
(http://bio.dfci.harvard.edu/Tools/rankpep.html). We
hypothesized that the conjugation of multiple pep-
tidesontoasinglescaffoldwouldallowtheantigensto
be taken up and presented at a higher density to
overcometheactivationthresholdofmouseCD4Tcells.
Furthermore, nanoparticulate SWNT WT1Pep427 con-
jugates may alter trafficking and clearance both intra-
cellularlyandatthetissuelevelinvivo,suchasproviding
a depot effect. This could potentially, in turn, enhance
the induction of a peptide-specific IgG response.
CD4 T cell stimulation experiments similar to those
performed with human donor cells were performed
with lymphocytes isolated from the spleens of BALB/c
mice. Cells were stimulated with peptide alone, pep-
tide-SWNT conjugates, and SWNTs alone. No peptide
speciﬁc response was detected in an IFN-γ ELISPOT
assay of mouse CD4 cells in vitro (see Supporting
Information), conﬁrming the relatively weak immuno-
genicity of WT1Pep427 in mouse immune cells. For
vaccination studies in vivo, BALB/c mice were immu-
nized with ﬁve diﬀerent constructs: SWNT alone, WT1-
Pep427 peptide alone, WT1Pep427 conjugated to
SWNT (WT1Pep427/SWNT), WT1Pep427 mixed with
adjuvant Titer Max, or the WT1Pep427/SWNT mixed
withTiterMax.Afterthreeandfourimmunizations,the
peptide-speciﬁc serum IgG responses were evaluated
by ELISA assay. Among the ﬁve immunization groups,
only the mice injected with peptide/SWNT construct
mixedwithTiterMaxinducedsigniﬁcantIgGresponses
speciﬁc for WT1Pep427 peptide (Figure 7A,B). This
antibody response was reproducibly observed in re-
peated trials in diﬀerent cohorts of mice. In all experi-
ments,noIgGresponseappearedtobedirectedagainst
the SWNTs, although the amount of SWNTs on the
plates could not be quantiﬁed. The mice immunized
with SWNTs, WT1Pep427 alone, WT1Pep427/SWNT, or
the WT1Pep427 mixed with TiterMax did not show
detectable IgG responses. No IgM response was ob-
served in any of the groups either (see Supporting
Information), suggesting there was adequate CD4 T
cell help in SWNT WT1Pep427 treated mice to pro-
mote antibody class switch. Three immunizations also
induced the speciﬁc IgG response to WT1Pep427 pep-
tide, but to a lesser degree than four immunizations,
conﬁrmingthatrepetitiveimmunizationswererequired
for boosting the antibody response.
DISCUSSION
In the present study we demonstrated successful
conjugation of large numbers of MHC class II peptide
ligandsontosolubilizedSWNTscaﬀolds.Thenanotube
Figure6. GenerationofIFN-γCD4responsesinvitroinhuman
cells.IFN-γELISPOTbyCD4TcellsstimulatedwithSWNT,WT1-
Pep427, or WT1Pep427/SWNT constructs. CD4Tcells from
a healthy donor were stimulated twice with APCs that were
pulsedwith SWNTs, WT1Pep427, or WT1Pep427/SWNT for
the entire culturing time (a), 1 h (b), or 15 min (c) as de-
scribedintheMethodssection.StimulatedTcellswerechal-
lenged in IFN-γ ELISPOT assay with the SWNT, WT1Pep427
peptide,ortheirrelevantcontrolpeptide.Theresultsrepre-
sent the mean spots in triplicate cultures (SD. The ﬁgures
show one representative data set from multiple similar ex-
periments. Experiments included PHA as a positive control,
notshown.Statisticalanalyseswereperformedusingtwo-way
ANOVA with Bonferroni post-test (**p < 0.01, ***p < .001).
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scaﬀold (SWNT 4FB) was a polydisperse mixture con-
taining ∼0.4 mmol/g of aldehyde groups. The poly-
dispersity ofnanotube length mayconfer somebeneﬁt,
as it may oﬀer the potential to direct nanotube delivery
to several cellular pathways, inducing a broader diver-
sity of immunologic responses. The peptide attach-
ment to the SWNTs formed a spectrally quantiﬁable
chromophore that correlated well with the starting
number of aldehyde groups. This linkage is a chemi-
cally robust bis-aryl hydrazone that should be stable in
physiologic conditions long enough for internalization
and traﬃcking. By spectrophotometrically quantifying
the bond formed between the peptides and SWNTs,
the amount of covalently bound peptide is more pre-
cisely calculated, and the calculation is unaﬀected by
free peptide. We then used these constructs to investi-
gate interactions between SWNTs and human imma-
ture dendritic cells, the primary APC of the human
immune system. The SWNT 4FB scaﬀold was robustly
internalizedand noncytotoxic toDCsup to100μg/mL.
The SWNT 4FB and SWNT WT1Pep427 were rapidly
internalized and accumulated by DCs, with an uptake
pattern consistent with macropinocytosis and subse-
quent shuttling to MHC class II compartments. We
expected the antigenic peptide to be released from
SWNTsandpresentedbytheAPCstoinduceapeptide-
speciﬁc IgG response. While human CD4 responses to
SWNT WT1Pep427werecomparabletothatachieved
withpeptidealoneinvitro,themouseCD4responseto
WT1Pep427 in vitro, as measured by IFN-γ production
in an ELISPOT assay, was poor regardless of conjuga-
tion to SWNTs. These results are consistent with the
known poorly immunogenic properties of WT1Pep427
inmouseimmunecells.Whenvaccinationstudieswere
performed in vivo in mice, however, we observed that
despitean apparentlyweakIFN-γ CD4response invitro,
afterfour immunizations with SWNT WT1Pep427 con-
jugates, there was a signiﬁcantly increased peptide
speciﬁc IgG response. These results demonstrated the
following: (1) Successful delivery and presentation of
the peptide in vivo can be achieved by use of SWNTs.
This suggests that although the same amount of
peptide was injected into the mice, the scaﬀold func-
tion of the SWNT may be to improve antigen uptake
and presentation by APCs. The SWNT may oﬀer better
traﬃcking and the delivery of the antigens, such as a
tissue depot eﬀect, since normally only a small fraction
of the dose gains access to the APCs when drugs or
antigens are injected in soluble form. Another possibi-
lity is that although WT1Pep427 typically produces
Th1-type responses (i.e., IFN-γ producing CD4 cells),
conjugation to SWNTs redirects the immune response
toward a Th2 response. This would shift the response
awayfromIFN-gproducingCD4cellsandmoretoward
IL-4 mediated responses. Although IL-4 responsive T
cells were not assessed in these experiments, nano-
particulate vaccines have been known to shift re-
sponses from Th1 to Th2 responses with increasing
particle sizes,
15 and these responses are being investi-
gated by our group. (2) The adjuvant eﬀect is also
necessary for the peptide/SWNTs to induce IgG re-
sponses, as the peptide/SWNT construct did not induce
asigniﬁcantIgGresponseeither.Thisrequirementisnot
surprising, as a variety of adjuvants have been shown
to be necessary for eliciting antibody responses. The
results also suggest that the SWNTs may not stimulate
innateimmunityastheclassicadjuvantsdo.(3)Peptide
mixed with adjuvant did not induce any antibody
response. This indicates that adjuvant alone is not
suﬃcienttohelpaweakMHCclassIIpeptidetoinduce
Figure 7. Serum IgG response is speciﬁc to WT1Pep427 pep-
tide. Mice were vaccinated with the indicated constructs
for four timesanda weekafter ﬁnal immunization,seracol-
lected from the mice were tested in an ELISA against the
indicatedantigensata(a)1:200dilutionand(b)1:2000dilu-
tion. The results represent the mean values in triplicate
assay(SD.Theﬁguresshowrepresentativedatafrommul-
tiple similar experiments.
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an IgG response. Finally, it is intriguing that the con-
jugation ofthe peptide to SWNTs could bypassthe use
of a traditional carrier protein such as keyhole limpet
hemocyanin (KLH). In general, the generation of anti-
body responses against poorly immunogenic tumor
antigens is best achieved by conjugating the peptides
to a large carrier protein (like KLH), plus an adjuvant.
37
One explanation for the immune response without a
carrierproteinistheuseofalongpeptidethathasCD4
epitopes in it.
25,26
Because no immunologic responses to SWNT 4FB
alone were observed, using the SWNTs to deliver a
poorly antigenic peptide would thus avoid a nonspe-
ciﬁc immune response and enable the generation of a
morefocused,antigen-speciﬁcimmune response.Over-
all, this study demonstrates the potential of SWNTs to
deliver poorly immunogenic antigens to the immune
system, and therefore they are promising tools to
explore ways to improve vaccine therapy against
cancers and other weakly immunogenic targets.
METHODS
Peptides and Reagents. The peptides used in this study were
synthesized by Genemed Synthesis, Inc. (San Antonio, TX) with
more than 70% purity. These include a HLA-DR.B1-binding
peptide WT1Pep427 derived from human WT1 (RSDELVR-
HHNMHQRNMTKL) that was used for immunizing mice. A hu-
man JAK-2-derived HLA-DR.B1-binding peptide JAK2-DR
(GVCVCGDENILVQEF) and BCR.ABL-derived peptide B3A2
(IVHSATGFKQSSKALQRPVASDFE) were used as irrelevant
controls.
35 The peptides were dissolved in DMSO and diluted
in saline at 5 mg/mL and stored at  80  C until use. Human
granulocyte-macrophage colony-stimulating factor (GM-CSF),
interleukin (IL)-1β, IL-4, IL-6, tumor necrosis factor (TNF)-R,
prostglandin E2 (PGE2) were also used. Cell isolation kits for
human CD14 and CD4 were purchased from Miltenyi Biotec
(Bergisch Gladbach, Germany). Human and mouse interferon
(IFN)-γ, and mouse IL-4 ELISPOT kits were purchased from
Mabtech (Sweden). The horseradish peroxidase (HRP)-anti-
mouse IgG and IgM were purchased from Southern Biotechnol-
ogy Associate Inc. (Brimingham, AL). Adjuvant Titer Max gold
was purchased from Sigma-Aldrich Co (St. Louis, MO).
Functionalization of SWNTs. SWNTs produced via the high
pressure carbon monoxide method were obtained from Uni-
dym,Inc.(Sunnyvale,CA).Thenanotubeswere100 1000nmin
length and 0.8 1.2 nm in diameter, as characterized by the
manufacturer. The nanotubes were covalently functionalized on
their sidewalls according to previously described techniques.
27
This reaction serves to both solubilize the nanotubes and
introduce primary amines (SWNT NH2). Further purification
was accomplished through the use of a C18 Sep-Pak reverse
phase cartridge (Waters, Milford, MA), with hydrophilic impu-
rities removed from the relatively hydrophobic SWNTs by
washing with 20 25% acetonitrile in 0.1 M tetraethyl ammo-
nium acetate, pH 7. The product SWNT NH2 was eluted from
thecartridgewithatleast50% acetonitrile.TheSWNT NH2solid
was lyophilized to a dark brown solid and analyzed by UV vis
spectroscopy using a Spectramax M2 spectrophotometer
(Molecular Devices, Sunnyvale, CA), transmission electron mi-
croscopy (Philips EM-201, Royal Philips Electronics, Amsterdam,
Netherlands), and Raman spectroscopy (inVia microRaman
system,RenishawPlc,Gloucestershire,UnitedKingdom).Amine
content was assayed by a quantitative Kaiser ninhydrin assay
(Fluka).
Modification of SWNT NH2 with Succinimidyl 4-Formyl Benzaldehyde.
The purified SWNT NH2 in 50% acetonitrile/water was diluted
into a reaction buffer of 0.1 M phosphate, 0.15 M NaCl, pH 8 to
20% acetonitrile, and 3 5 g/L of SWNT in the final reaction
mixture. To the reaction was added a 10- to 20-fold excess (per
amine)ofsuccinimidyl4-formylbenzaldehyde(ThermoScientific)
dissolved in DMSO. The reaction was allowed to proceed for 2 h
after which the pH was raised to 9 10to quench remaining free
linker.ThequenchedreactionwasthenpurifiedonaC18reverse
phase cartridge as previously described. The remaining amines
on the SWNT 4FB solid were quantified by a Kasier ninhydrin
assay,
36whichdemonstratedthat>95%ofamineswerecapped
with benzaldehyde groups. The incorporated benzaldehyde
groups were quantified spectrophotometrically by reaction
with0.5mM2-hydrazinopyridine.Thisreactionformsaspectro-
photometrically quantifiable bis-aryl hydrazone bond (λmax =
350 nm, ε = 18000). This reaction was referenced against the
reaction buffer alone and the inherent absorbance of the
SWNT NH2 at 350 nm.
Modification of WT1Pep427 with Hydrazine Linker. The WT1Pep427
peptide was reconstituted in a reaction buffer of 0.1 M phos-
phate, 0.15 M NaCl, pH 7.5. To the peptide was added a 2-fold
excess of succinimidyl hydrazine nicotinamide (Pierce). After 3
h, the peptide was purified from excess linker by size exclusion
chromatography on an 1800 Da molecular weight cutoff poly-
acrylamide gel column (D-Salt, Thermo Scientific) into a 0.1 M
MES, 0.15 M NaCl, pH 5.6 buffer. The elution profile was tracked
through absorbance at 280 nm, and the purity of the peptide
wasconfirmedbyHPLC.Theincorporatedhydrazinewasassayed
by reaction of an aliquot of the purfied WT1Pep427-HyNic with
0.5 mM 4FB-PEG (Solulink). This reaction forms a spectropho-
tometricallyquantifiablebis-arylhydrzonebond(λmax=354,ε=
29000).Theremainingfreeamineswerequantifiedthroughthe
quantitative Kaiser ninhydrin assay.
Conjugation of SWNT 4FB and WT1Pep427-HyNic. The purified
SWNT 4FB and WT1Pep427-HyNic were reacted in a buffer of
0.1 M MES, 0.15 M NaCl, pH 5.5 with 20% acetonitrile in the
reaction mixture. Typically, the SWNT concentration was at
0.5 1 g/L, and the peptide was added at a ratio of 0.5 1 mmol
of peptide per gram of SWNTs. The reaction mixture was then
purified through a C18 cartridge (Waters), with free peptide
removed by washing with 20% acetonitrile in 0.1 M TEAA. The
pure SWNT WT1Pep427 conjugate was eluted with 50% acet-
onitrile in water. The conjugate was lyophilized to a dark brown
solidwhichwasthenreconstitutedwithDMSO(99.8%þbiotech
grade, Sigma) prior to use in biological assays and vaccinations.
SWNT WT1Pep427 was typically dissolved in DMSO, diluted
intoPBS,andthefinalconcentration ofDMSOinallassaymedia
and injection formulations was less than 0.15% and vehicle
controls contained identical amounts of DMSO. For SWNT 
WT1Pep427(FITC) conjugates, a custom synthesized peptide
was ordered from Solulink, Inc. (San Diego, CA) containing a
N-terminal hydrazino nicotinamide and a fluorescein on the
lysine side chain of the peptide, and a similar conjugation
reaction was performed.
FluorescentLabelingofSWNT. ThepurifiedSWNT NH2material
was reconstituted in a reaction buffer of 0.1 M phosphate, 0.15
M NaCl, pH 8 containing 20% acetonitrile to keep the SWNTs
from aggregating. To the SWNTs was added the amine reactive
succinimdyl ester of Alexa Fluor 555 (Invitrogen), or an equi-
molar mixture of an amine reactive benzaldehyde terminated
linker (PEG4/PFB, SoluLink) and a succinimidyl ester derivative
ofAlexaFluor568(Invitrogen),atamolarexcessofdye/linkerto
amine. SWNT WT1Pep427(FITC) conjugates were similarly la-
beled with a succinimidyl ester of HiLyte Fluor 647 (Anaspec,
Inc.). The resulting products were purified on a 10-DG silica gel
benchtopsizeexclusioncolumnintophosphatebufferedsaline.
Dyeloadingwassimilarforboththeamine(SWNT NH2 AF555)
and aldehyde (SWNT 4FB AF568) functionalized materials,
A
R
T
I
C
L
EVILLA ET AL. VOL. 5 ’ NO. 7 ’ 5300–5311 ’ 2011
www.acsnano.org
5310
with a range of 0.03 0.1 mmol of dye per gram of SWNTs,
calculated spectrophotometrically.
High Performance Liquid Chromatogrpahy (HPLC). All chromato-
graphicanalyseswereperformedonaBeckmanCoulterSystem
Gold HPLC system equipped with inline diode array spectral
analysis and fluorescence detectors. Data were exported and
analyzed using Prism software (GraphPad). All columns were
GeminiC18(Phenomenex).SolventAwasHPLCgrade0.1Mtetra
ethyl ammonium acetate (TEAA), and solvent B was 100%
acetonitrile. Elution gradients were either 0 to 100% B over 30
min,or20%Bfor10minfollowedbya20to100%gradientover
30 min.
Live Cell Microscopy. Immature (day 5) dendritic cells were
seeded into 3.5 cm Mattek tissue culture dishes with coverglass
bottoms. The cells were supplemented with 5% autologous
plasma. Cells were imaged on a Zeiss confocal microscopy
system equippedwith atemperature-controlledstage.Imaging
parameterswereverifiedagainstcontroluntreatedcellsamples
to rule out autofluorescence. The labeled constructs (in PBS)
wereaddedtotheDCsat1 10μg/mL, in1 2mLtotalvolume.
Cells were imaged either immediately after the addition of
labeled constructs, or after washing with culture medium. Nuclei
in live cells were stained with Hoechst 33342 (Invitrogen).
Lysosomes were imaged with Lysotracker dye (Invitrogen),
and clathrin mediated cytosis was imaged with Texas Red
labeledtransferrin (Invitrogen)perthemanufacturer suggested
protocols.
Animals and Immunizations. Healthy female Balb/c mice (6 8
weeks old; Taconic) were housed in the Memorial Sloan-Ketter-
ing Cancer Center animal facility. Animals were cared for under
institutionally approved animal care and use protocols. The
mice were each vaccinated subcutaneously with 20 μg
WT1Pep427 peptide, or the peptide conjugated to SWNTs in
PBS mixed with an equal volume of TiterMax. SWNTs were
suspended in PBS by dissolving solid SWNT 4FB of SWNT 
WT1Pep427 in minimal DMSO with subsequent dilution into
PBS. Identical procedures and amounts of DMSO were used for
vaccinationwitheitherpeptides,nanotube-peptideconjugates,
or nanotubes alone. The amount of SWNTs alone or peptide
alone for vaccination was always adjusted to equal nanotube
mass in the peptide/SWNT conjugates. Animals were vacci-
nated with 20 μg peptide per vaccination. For nanotube pep-
tideconjugateswhereSWNTscontained0.4mmol/gofpeptide,
20 μg of peptide correlated with ∼20 μg of SWNT mass.
Vaccinations were performed three to four times every two to
three weeks and mice were sacrificed for analyses one week
after final vaccination.
Enzyme-Linked Immunosorbent Assay (ELISA) for Antibody Detection.
Maxisorpplates(96-well)(Nunc,Naperville,IL)werecoatedwith
1 μg of antigen per well in 50 μL of PBS overnight at 4  C. The
wellswereblockedwith300μLof2%BSAinPBSfor2hat37 C.
The plates were washed six times in PBS, and 100 μL of mouse
serum diluted in 2% BSA/PBS was added to triplicate wells for 2
h. After the cells were washed, secondary mAbs of antimouse
IgG or IgM conjugated to horseradish peroxidase (HRP) was
added, and the Ab responses were detected by TMB substrate
(OwingsMill,MD),followedbyastopsolutionof1MH2SO4.The
plates were read at 450 nm wavelength in an Spectramax M2
(MolecularDevices)platereader.KLHandastandardpolyclonal
mouse anti-KLH serum were used as a positive control for each
experiment. To test antigen binding to wells, identical ELISA
assays were also performed with more hydrophobic Polysorp
plates with very similar results. The amount of SWNT adsorbed
to the plate could not be directly calculated, however.
Generation of Human Monocyte-Derived Dendritic Cells (DCs). After
informed consent on Memorial Sloan Kettering Cancer Center
Institutional Review Board approved protocols, peripheral blood
mononuclearcells(PBMC)fromhealthydonorswereobtainedby
Ficoll density centrifugation. CD14þ monocytes were isolated
by positive selection using mAb to human CD14 coupled with
magnetic beads (Miltenyi Biotec). DCs were generated from
CD14þ cells, by culturing the cells in RPMI 1640 medium
supplemented with 1% autologous plasma (AP), 500 units/mL
recombinant IL-4, and 1000 units/mL GM-CSF. On days 2 and 4
of incubation, fresh medium with IL-4 and GM-CSF was either
addedorreplacedhalfoftheculturemedium.ForSWNTuptake
experiments and microscopy, immature DCs (day 5) were
seededintomultiwelltissuecultureplatesorcoverglassbottom
microscopy dishes (Mattek) and assayed as described. Alamar
blue, ATP lite, and bisbenzimide assays (Invitrogen) were per-
formed as described by the manufacturer.
Isolation and In Vitro Stimulation of CD4 T-Cells. The CD4þ T cell
fraction from human PBMC was isolated by positive selection
using mAbs to human CD4 coupled with magnetic beads
(Miltenyi Biotec). For human in vitro studies, T cells were stimu-
lated with CD14þ cells as APC (T cells: APC ratio: 10:1), in the
presence of 10 μg/mL peptide, SWNTs, or the peptide/SWNT
conjugates,and10ng/mLIL-15intheRPMI1640supplemented
with 5% AP. A week later, the same stimulation protocol was
performed usingautologousDCsasAPCsataTcell/APCratioof
30:1. A week after secondary stimulation, the peptide-specific
CD4 T cell response was examined by IFN-γ enzyme-linked
immunospot (ELISPOT) assay.
IFN-γ ELISPOT. For human studies, HA-Multiscreen plates
(Millipore) were coated with 100 μL of mouse antihuman IFN-
γ antibody (10 Ag/mL; clone1-D1K; Mabtech) inPBS, incubated
overnight at 4 C, washed with PBS to remove unbound anti-
body, andblocked with RPMI 1640/10% AP for 2 hat 37 C. CD4
þ T cells were plated with autologous CD14þ APCs (10:1 E/APC
ratio), and various test peptides, SWNTs, or conjugates were
added to the wells at 20 μg/mL. Negative control wells con-
tained APCs and T cells without peptides or APCs and T cells
with irrelevant peptides JAK2-DR. Phytohemagglutinin (PHA,
Sigma) at a concentration of 10 μg/mL was used as a positive
controlfortheassay.Microtiterplateswereincubatedfor20hat
37  C and then extensively washed with PBS/0.05% Tween and
100μL/wellbiotinylateddetectionantibodyagainsthumanIFN-
γ (2 μg/mL; clone 7-B6-1; Mabtech) was added. Plates were
incubated for an additional 2 h at 37  C, and spot development
wasdone asdescribed inref.Spot numbers wereautomatically
determined with the use of a computer-assisted video image
analyzer with KS ELISPOT 4.0 software (Carl Zeiss Vision). Data
were plotted and interpreted using Prism (GraphPad) data
analyses software.
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